POTP starts melanoma Phase II

Point Therapeutics (POTP) began a Phase II trial of talabostat (PT-100) plus cisplatin in 54 patients with advanced metastatic melanoma. The primary endpoint of the trial is overall tumor response. At the approximate mid-point of the study, tumor response rates will be compared to historical response rates of current therapies to determine whether the trial should be continued. Other secondary study endpoints include complete response rate, duration of tumor response, time to disease progression, survival and incidence of severe neutropenia and anemia. ...